Plutonium is a radioactive metal that serves two major roles: it fuels nuclear weapons and powers deep-space spacecraft. It is also one of the most radiotoxic substances known, capable of causing cancer when even tiny amounts enter the body. What plutonium “does” depends entirely on context, whether you’re talking about its use in energy and defense, its behavior inside the human body, or its movement through the environment.
How Plutonium Is Used
Plutonium-239, the most well-known isotope, is one of the primary fuels used in nuclear weapons. It contains a high proportion of fissile material, meaning its atoms split easily in a chain reaction that releases enormous energy. This same property makes it useful in nuclear power. Several countries use plutonium as reactor fuel, though the United States currently does not. U.S. commercial reactors do create plutonium as a byproduct during normal operation: spent nuclear fuel from American reactors contains about one percent plutonium by weight. Some of that plutonium actually fissions inside the reactor as part of the chain reaction, contributing to the plant’s power output.
Plutonium-238, a different isotope with a much shorter half-life of about 88 years, plays a completely different role. It emits steady heat as it naturally decays, and NASA has used it as a power source on more than two dozen space missions over the past 50 years. Radioisotope power systems convert that heat into electricity to run computers, science instruments, and other hardware on missions like the Perseverance rover on Mars and the New Horizons spacecraft exploring beyond Pluto. Plutonium-238’s combination of high power density (a small amount produces substantial heat) and a decades-long lifespan makes it the only radioisotope that consistently meets the requirements for deep-space power.
What Happens When Plutonium Enters the Body
Plutonium’s danger to humans comes almost entirely from its radioactivity, not its chemistry as a heavy metal. While metals like lead and arsenic cause harm through chemical toxicity, plutonium’s chemical toxicity is minor compared to the damage caused by its radiation. The European radiotoxicity classification system places plutonium-239 in Group 1, the “Very High Radiotoxicity” category, while uranium-235 sits in Group 4, the lowest.
The primary threat is alpha radiation. Alpha particles are heavy, slow-moving bits of radiation that can’t penetrate skin or even a sheet of paper. But when plutonium is inhaled or ingested and lodges inside tissue, those alpha particles slam into cells at point-blank range. The body absorbs all of the alpha energy emitted by retained plutonium, and the damage concentrates in three organs: the lungs, bones, and liver. These are the tissues where plutonium accumulates and stays for extended periods.
Plutonium-239 has a biological effective half-life of roughly 197 years, meaning the body eliminates it extraordinarily slowly. Only about 0.05% of ingested plutonium is absorbed through the gut, so swallowing it is far less dangerous than inhaling it. Inhaled plutonium oxide particles can remain in the lungs for years. Other plutonium compounds clear from the lungs in weeks but redistribute to bone and liver, where they continue irradiating surrounding cells. The bone surface is considered the critical organ for radiation dose.
Cancer Risk From Plutonium Exposure
Lung cancer is the most serious cancer linked to plutonium exposure. The clearest evidence comes from studies of workers at the Mayak nuclear facility in Russia, where thousands of people were exposed to plutonium during the early decades of the Soviet nuclear weapons program. In a study of over 14,600 Mayak workers hired between 1948 and 1982, researchers tracked 486 lung cancer deaths over a follow-up period stretching to 2008. After adjusting for smoking and external radiation exposure, 22% of those lung cancer deaths were attributed to plutonium exposure.
The dose-response relationship was strikingly clear. Even among workers whose plutonium doses were relatively low, researchers found statistically significant increases in lung cancer risk. Women appeared more susceptible than men: at age 60, the excess relative risk per unit of absorbed radiation dose was about three times higher for females than for males. These findings held up regardless of how the data was sliced by dose range, reinforcing that there is no obvious “safe” threshold for plutonium exposure.
Beyond lung cancer, plutonium’s tendency to concentrate in bone raises the risk of bone cancers, and its accumulation in the liver creates potential for liver cancers, though lung cancer dominates the epidemiological evidence.
How Plutonium Behaves in the Environment
Once released into the environment, plutonium generally binds tightly to soil and moves slowly. But “slowly” is a relative term for a substance with a half-life of 24,000 years for plutonium-239 and 6,560 years for plutonium-240. Research on plutonium transport through soil has shown that its mobility varies enormously depending on soil type and rainfall patterns. In column experiments comparing sandy and clay-rich soils under simulated tropical and arid conditions, the measurement describing how tightly plutonium sticks to soil particles spanned six orders of magnitude, from essentially immobile to moderately mobile.
Surprisingly, episodic rainfall in arid regions pushed plutonium through soil faster than the steady, frequent rain of tropical climates. And plutonium contamination that had aged for over 30 years in sandy soil showed higher mobility than freshly deposited plutonium, likely because the plutonium-bearing particles had weathered over time. In tropical sandy soil systems, researchers found that low-intensity but frequent rain events could mobilize aged plutonium contamination over weeks rather than the years previously assumed. This matters for ecosystems near historical nuclear test sites, where plutonium deposited decades ago may be more mobile than models predict.
Treatment for Internal Contamination
If someone inhales or ingests plutonium, there is an FDA-approved treatment. Chelation therapy uses compounds called DTPA (available in two forms, calcium-DTPA and zinc-DTPA) that bind to plutonium circulating in the body and help flush it out through the kidneys. The treatment works best when plutonium is still in a soluble form moving through the bloodstream. Once plutonium becomes trapped in bone, chelation is significantly less effective.
Timing matters. Calcium-DTPA is more effective in the first 24 hours after contamination, so it’s given as the initial dose. After that, zinc-DTPA is preferred for ongoing treatment because it causes less depletion of essential minerals like zinc. The main side effect of chelation therapy is the loss of these nutritional metals, which can be countered with oral supplements. For pregnant women, zinc-DTPA is the recommended option because animal studies suggest calcium-DTPA may cause fetal harm. Treatment can be given intravenously or inhaled through a nebulizer, with the inhaled route specifically recommended when contamination occurred only through breathing.
Why Plutonium Occupational Limits Are So Strict
Because plutonium is so radiotoxic and stays in the body for so long, the allowable workplace exposure is vanishingly small. The annual limit on intake for plutonium-239 through inhalation is set at 0.006 microcuries, a quantity so tiny it’s essentially invisible. For context, that limit is designed to keep a worker’s total committed radiation dose below 5 rems per year to the whole body, or 50 rems to the most affected organ (in plutonium’s case, the bone surface). Workers in facilities that handle plutonium operate under strict air monitoring, protective equipment, and contamination control protocols because even microscopic amounts of inhaled plutonium can deliver meaningful radiation doses over a lifetime.